Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on July 24, 2024, covering the event date of July 19, 2024. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "PHIO."
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status regarding stock listing requirements.
Material Changes
On July 19, 2024, the Company received written notice from The Nasdaq Stock Market LLC confirming it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)). This compliance was achieved following a one-for-nine reverse split of the Company's common stock, which became effective on July 5, 2024.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the resolution of the prior listing deficiency. The primary unusual item addressed is the successful implementation of the reverse split to maintain Nasdaq listing status.
Investor Verification Checklist
- Verify the effective date and ratio of the one-for-nine reverse split (effective July 5, 2024).
- Confirm the current minimum bid price of the stock to ensure continued compliance with Nasdaq Listing Rule 5550(a)(2).
- Review the prior Form 8-K filed on July 2, 2024, for detailed information regarding the reverse split mechanics.
- Monitor future filings for any additional Nasdaq compliance notices or financial updates.